Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cystic fibrosis respiratory infections

Bums, J.L., Van Dalfsen, J.M., Shawar, R.M., Otto, K.L., Garber, R.L., Quan, J.M., Montgomery, A.B., Albers, G.M., Ramsey, B.W., Smith, A.L. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179 (1999) 1190-1196. [Pg.251]

Bums JL, Van Dalfsen JM, Shawar RM. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179 1190-1196, 1999. [Pg.501]

Drug formulations In February 2010, a solution of aztreonam for inhalation, formulated with lysine, was approved by the US FDA for the treatment of respiratory symptoms in patients with cystic fibrosis and infected with Pseudomonas aeruginosa [75 ], a bacterium that has always been difficult to treat with antibiotics, especially when it grows in biofilm, as is the case in the airways. So far, no new types of adverse effects have been found [76 ]. A key problem will be the development of resistance to this new formulation [77 ]. [Pg.495]

Cystic fibrosis (CF) is a hereditary disease of abnormal fluid secretion. It affects cells of the exocrine glands, such as intestine, sweat glands, pancreas, reproductive tract, and especially the respiratory tract. The disease affects about 1 in 2500 infants of the Caucasian population to varying degrees of seriousness. Patients produce thickened mucus that is difficult to get out of the airway. This leads to chronic lung infection, which progressively destroys pulmonary function. [Pg.26]

A 1-year-old toddler with cystic fibrosis (CF) is seen by his physician for an upper respiratory infection with Pseudomonas aeruginosa. He is started on oral norfloxacin and referred to a CF center as i potential candidate for gene therapy. Prior genetic testing of the patient identified the mutation causing cystic fibrosis as a 3-base-pair deletion in esan 10 of the CF gene. The nucleotide sequences f codons 506-511 in this region of the normal and mutant alleles are compared below. [Pg.111]

The spectrum of respiratory tract infections (RTI) can vary from the common cold to acute or chronic bronchitis to community-acquired pneumonia to nosocomial pneumonia and aspiration pneumonia to ventilator-associated pneumonia to chronic pneumonia (in cystic fibrosis, histoplasmosis, tuberculosis, etc.). Important complications are lung abscess and pleural empyema that will often need drainage and prolonged antimicrobial treatment (>6 weeks). [Pg.525]

A 16-year-old girl, a cystic fibrosis patient, is diagnosed with a ciprofloxacin-resistant Pseudomonas aeruginosa lower respiratory tract infection. [Pg.523]

Indications Management of cystic fibrosis patients to improve pulmonary function and protection against respiratory tract infections... [Pg.259]

F. Role in therapy Pulmozyme is a mucolytic enzyme used in the treatment of cystic hbrosis. Although it is not a cure, domase alfa is an effective mucolytic for adjunctive treatment. AU compliant patients with cystic fibrosis, irrespective of disease severity, who produce purulent sputum are potential candidates for Pulmozyme therapy. It is useful for liquefying the thick mucus secreted by cystic fibrosis patients, and causes both objective improvement (as measured by pulmonary function testing) and subjective symptomatic improvement. Pulmozyme reduces the frequency of respiratory infections requiring parenteral antibiotics and improves pulmonary function. [Pg.261]

Aerosolized DNase (dornase) is a therapeutic protein designed for alveoli delivery to achieve local effects in the deep lung. Aerosolized DNase is formulated as a pulmonary dosage form, targeted for deep-lung delivery to reduce opportunistic infections due to the increased viscosity of mucus in the lung that affects respiratory function in patients with cystic fibrosis. [Pg.344]

An additional transferase that uses acetyl-CoA as a substrate sometimes acetylates one mannuronate unit. The disaccharide irnits are then inserted into the growing chain. An additional modification, which occurs after polymerization, is random C5 epimeriza-tion of unacetylated D-mannuronate residues to l-guluronate.136 182 Formation of alginate is of medical interest because infections by alginate-forming bacteria are a major cause of respiratory problems in cystic fibrosis.182... [Pg.1153]

Children with cystic fibrosis lose excessive amounts of salt in perspiration and become dehydrated readily. A salty taste of the skin and an elevated chloride concentration of sweat are traditional diagnostic symptoms.3 More serious problems arise from progressive respiratory failure and inadequate pancreatic secretion. Lung infections with Pseudomonas aeruginosa are the major cause of death. The CFTR gene is expressed in many tissues, especially those of the mucous membranes. [Pg.1513]

Pseudomonas aeruginosa is another major human pathogen that causes disease in patients with impaired host defenses.27 Ps. aeruginosa is primarily associated with ultimately fatal chronic respiratory infection in cystic fibrosis and other forms of bronchiectasis.28 Despite strong inflammatory... [Pg.331]

Anti-infectious agents also play a key role in the treatment of cystic fibrosis, and respiratory infections are treated with appropriate antibiotic agents.16 89 In particular, azithromycin has shown considerable... [Pg.382]

Genetic alterations or abnormalities of germ cells, some of which can be caused by toxicant exposure, can be manifested by adverse effects on progeny. The important health effects of these kinds of alterations may be appreciated by considering the kinds of human maladies that are caused by inherited recessive mutations. One such disease is cystic fibrosis, in which the clinical phenotype has thick, dry mucus in the tubes of the respiratory system such that inhaled bacterial and fungal spores cannot be cleared from the system. This results in frequent, severe infections. It is the consequence of a faulty chloride transporter membrane protein that does not properly transport Cl ion from inside cells to the outside, where they normally retain water characteristic of healthy mucus. The faulty transporter protein is the result of a change of a single amino acid in the protein. [Pg.189]

Boucher, J.C., Yu, H., Mudd, M.H., Deretic, V. Mucoid Pseudomonas aeruginosa in cystic fibrosis characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 65 (1997) 3838-3846. [Pg.251]

Carmen is a pale 20-year-old lady. Like many cystic fibrosis patients, she was diagnosed when she was a baby her problem was suspected when she suffered repeated respiratory infections and failed to gain weight as expected. Patients with cystic fibrosis secrete a high concentration of NaCl in their sweat and this forms the basis of an early diagnostic test for the condition. [Pg.62]

Most children with cystic fibrosis are diagnosed within one year of birth. Often the symptoms observed in a child, which eventually lead to diagnosis, are malabsorption, failure to gain weight and recurrent respiratory infections. [Pg.219]

Nutrient malabsorption also occurs in the genetic disease cystic fibrosis. This disease arises from a mutation in the chloride ion transporter, and results in pancreatic insufficiency as well a.s respiratory difficulties. Treatment of the malabsorption symptoms of cystic fibrosis involves supplementation with pancreatic enzymes and synthetic water-soluble versions of the fat-soluble vitamins. The labored breathing and respiratory infections due to the disease cannot be treated by dietary intervention. [Pg.152]

Dornase alfa is human recombinant deoxyribonuclease. Daily therapy with dornase alfa in patients with cystic fibrosis can reduce the frequency of respiratory infections and improve lung function in patients with bronchiectasis. [Pg.1185]

Bolus intravenous colistin (160 mg in 10 ml of saline tds) has been studied in a phase I open study during acute respiratory exacerbations in adults vvith cystic fibrosis and chronic P. aeruginosa infection patients without total indwelling venous access systems had mild to moderate injection-like pain (34). [Pg.2893]


See other pages where Cystic fibrosis respiratory infections is mentioned: [Pg.293]    [Pg.138]    [Pg.288]    [Pg.1050]    [Pg.158]    [Pg.358]    [Pg.145]    [Pg.7]    [Pg.136]    [Pg.202]    [Pg.1529]    [Pg.392]    [Pg.221]    [Pg.1025]    [Pg.403]    [Pg.382]    [Pg.383]    [Pg.508]    [Pg.243]    [Pg.219]    [Pg.253]    [Pg.74]    [Pg.108]    [Pg.206]    [Pg.235]    [Pg.233]    [Pg.246]    [Pg.1405]   
See also in sourсe #XX -- [ Pg.593 , Pg.597 , Pg.598 , Pg.599 ]




SEARCH



Cystic

Cystic fibrosis

Infections respiratory

© 2024 chempedia.info